Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding dries up.

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

Fortune Europe Inside Bavarian Nordic: The $3.3 billion Danish vaccine maker with the world's only cure for mpox Forbes Mpox Vaccine Maker’s Shares Continue Rising As Concern Over Virus Outbreak ...

Bavarian Nordic's vaccine has been used worldwide since 2022, after U.S. and European regulators backed it for use against a different strain of mpox that spread globally in 2022.

Looking ahead to the rest of the year, Bavarian Nordic aims to grow earnings some 26% to 30% over that same span. As for what could be next in the company’s travel health portfolio, Bavarian ...

The WHO’s declaration of an emergency has caused Bavarian Nordic’s shares to jump over 40%. The company's shares are up 51% since the start of the year, with its market cap at $3.28 billion.

Bavarian Nordic (BVNRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement ...